1033743-85-9

Basic information

• Product Name: 4-(7-bromo-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine
• Synonyms: 4-(7-bromo-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine;7-Bromo-2-chloro-4-(4-morpholinyl)-thieno[3,2-d]pyrimidine
• CAS NO: 1033743-85-9
• Molecular Formula: C10H9BrClN3OS
• Molecular Weight: 334.61996
• Mol File: 1033743-85-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.752
• CAS DataBase Reference: 4-(7-bromo-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(7-bromo-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine(1033743-85-9)
• EPA Substance Registry System: 4-(7-bromo-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine(1033743-85-9)

Safety Data

• Hazardous Substances Data: 1033743-85-9(Hazardous Substances Data)

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 41102-02-7 7-bromothieno[3,2-d]pyrimidine-2,4(1H,3H)-dione 
• 16233-51-5 1H-thieno[3,2-d]pyrimidine-2,4-dione 
• 110-91-8 morpholine 
• 41102-25-4 7-bromo-2,4-dichloroimidazo[2,1-f][1,2,4]triazine 

Downstream Products

• 1339925-28-8 (E)-3-(4-(N-(2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)sulfamoyl)phenyl)-N-hydroxyacrylamide 
• 1339925-36-8 (E)-methyl 3-(4-(N-(2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)sulfamoyl)phenyl)acrylate 
• 1339925-35-7 (E)-methyl 3-(4-(N-(2-chloro-4-morpholinothieno[3,2-d]pyrimidin-6-yl)sulfamoyl)phenyl)acrylate 

Relevant articles and documents

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α

Inhibition of phosphoinositide 3-kinase (PI3K) signaling through PI3Kα has received significant attention for its potential in cancer therapy. While the PI3K pathway is a well-established and widely pursued target for the treatment of many cancer types due to the high frequency of abnormal PI3K signaling, glioblastoma multiforme (GBM) is particularly relevant because the pathway is implicated in more than 80% of GBM cases. Herein, we report the identification of PI3K inhibitors designed to cross the blood-brain barrier (BBB) to engage their target where GBM tumors reside. We leveraged our historical experience with PI3K inhibitors to identify correlations between physicochemical properties and transporter efflux as well as metabolic stability to focus the selection of molecules for further study.